Biotek-snakken — September 2024
-
AstraZeneca :Dato-DXd Fails To Significantly Improve Overall Survival In Phase III Lung Cancer Trial https://proinvestor.com/investornyt/1211502/astrazeneca-dato-dxd-fails-to-significantly-improve-overall-survival-in-phase-iii-lung-cancer-trial
-
ArriVent Announces Positive Phase 1b Data For Firmonertinib In NSCLC With EGFR PACC Mutations https://proinvestor.com/investornyt/1211514/arrivent-announces-positive-phase-1b-data-for-firmonertinib-in-nsclc-with-egfr-pacc-mutations
-
2 Biotech Stocks To Watch In September 2024 https://proinvestor.com/investornyt/1211993/2-biotech-stocks-to-watch-in-september-2024
-
BridgeBio's BBP-812 Canavan Disease Gene Therapy Receives FDA RMAT Designation https://proinvestor.com/investornyt/1212014/bridgebios-bbp-812-canavan-disease-gene-therapy-receives-fda-rmat-designation
-
Godmorgen
-
Innovent Biologics : Phase 3 Trial Results Of Mazdutide In Type 2 Diabetes Presented At EASD 2024 https://proinvestor.com/investornyt/1212496/innovent-biologics-phase-3-trial-results-of-mazdutide-in-type-2-diabetes-presented-at-easd-2024
-
Ascendis Pharma Gets U.S. Orphan Drug Exclusivity For YORVIPATH In Adult Hypoparathyroidism https://proinvestor.com/investornyt/1212489/ascendis-pharma-gets-us-orphan-drug-exclusivity-for-yorvipath-in-adult-hypoparathyroidism
-
J&J's TREMFYA Receives FDA Approval For Moderately To Severely Active Ulcerative Colitis In Adults https://proinvestor.com/investornyt/1212487/jampjs-tremfya-receives-fda-approval-for-moderately-to-severely-active-ulcerative-colitis-in-adults
-
Board member purchases shares in Acarix
I dag kl. 14:02 ∙ MFN
Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces that Dr. Tony Daz, Board member of Acarix, purchased 2,000,600 shares in the company between September 9 and September 11 at an average price of USD 0.031 per share. His total ownership amounts to 2,000,600 shares.
"I have great faith in the company and its product. The Acarix system is a disruptive technology to rapidly rule out CAD in a cost-effective way and -
Godmorgen
-
FDA Oks Genentech's Tecentriq Hybreza As First & Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy https://proinvestor.com/investornyt/1213082/fda-oks-genentechs-tecentriq-hybreza-as-first-amp-only-subcutaneous-anti-pd-l1-cancer-immunotherapy
-
Immuneering Reports Positive Initial Data For IMM-1-104 In Phase 2a Pancreatic Cancer Trial;stock Up https://proinvestor.com/investornyt/1213091/immuneering-reports-positive-initial-data-for-imm-1-104-in-phase-2a-pancreatic-cancer-trialstock-up
-
Cidara Eliminates 30% Of Workforce To Prioritize Clinical Development Of CD388; Stock Down https://proinvestor.com/investornyt/1213096/cidara-eliminates-30-of-workforce-to-prioritize-clinical-development-of-cd388-stock-down
-
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
-
Der er gange i flere biotek i aften pga ESMO https://finance.yahoo.com/news/esmo-moderna-mrna-solid-tumour-101238212.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind